PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis

Europe • Euronext Milan • BIT:PHN • IT0005274094

61.9 EUR
-0.7 (-1.12%)
Last: Feb 6, 2026, 05:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

PHN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 15 industry peers in the Personal Care Products industry. PHN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PHN is valied quite expensively at the moment, while it does show a decent growth rate. With these ratings, PHN could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year PHN was profitable.
  • PHN had a positive operating cash flow in the past year.
  • In the past 5 years PHN has always been profitable.
  • In the past 5 years PHN always reported a positive cash flow from operatings.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • PHN has a Return On Assets of 20.17%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
  • Looking at the Return On Equity, with a value of 36.55%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • PHN has a Return On Invested Capital of 25.72%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
  • PHN had an Average Return On Invested Capital over the past 3 years of 17.21%. This is significantly above the industry average of 11.60%.
  • The last Return On Invested Capital (25.72%) for PHN is above the 3 year average (17.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROIC 25.72%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

  • PHN has a Profit Margin of 13.39%. This is in the better half of the industry: PHN outperforms 78.57% of its industry peers.
  • PHN's Profit Margin has declined in the last couple of years.
  • The Operating Margin of PHN (21.79%) is better than 100.00% of its industry peers.
  • PHN's Operating Margin has been stable in the last couple of years.
  • PHN has a better Gross Margin (97.13%) than 100.00% of its industry peers.
  • In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
Industry RankSector Rank
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PHN is creating value.
  • The number of shares outstanding for PHN remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for PHN has been reduced compared to 5 years ago.
  • The debt/assets ratio for PHN has been reduced compared to a year ago.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • PHN has an Altman-Z score of 10.48. This indicates that PHN is financially healthy and has little risk of bankruptcy at the moment.
  • PHN has a better Altman-Z score (10.48) than 100.00% of its industry peers.
  • The Debt to FCF ratio of PHN is 2.01, which is a good value as it means it would take PHN, 2.01 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of PHN (2.01) is better than 71.43% of its industry peers.
  • PHN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
  • PHN's Debt to Equity ratio of 0.24 is fine compared to the rest of the industry. PHN outperforms 64.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Altman-Z 10.48
ROIC/WACC3.23
WACC7.97%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.19 indicates that PHN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.19, PHN belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
  • A Quick Ratio of 1.86 indicates that PHN should not have too much problems paying its short term obligations.
  • PHN's Quick ratio of 1.86 is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.86
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • PHN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.84%, which is quite good.
  • PHN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.63% yearly.
  • PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.35%.
  • The Revenue has been growing by 16.59% on average over the past years. This is quite good.
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%

3.2 Future

  • PHN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.13% yearly.
  • Based on estimates for the next years, PHN will show a quite strong growth in Revenue. The Revenue will grow by 13.74% on average per year.
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 24.66, PHN is valued on the expensive side.
  • PHN's Price/Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Earnings ratio is at 27.93. PHN is around the same levels.
  • PHN is valuated quite expensively with a Price/Forward Earnings ratio of 25.35.
  • Based on the Price/Forward Earnings ratio, PHN is valued a bit more expensive than 64.29% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.77. PHN is around the same levels.
Industry RankSector Rank
PE 24.66
Fwd PE 25.35
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit more expensive than 64.29% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PHN is valued a bit more expensive than the industry average as 78.57% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 57.48
EV/EBITDA 13.78
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • PHN has an outstanding profitability rating, which may justify a higher PE ratio.
  • PHN's earnings are expected to grow with 15.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.95
PEG (5Y)1.69
EPS Next 2Y13.31%
EPS Next 3Y15.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • PHN has a Yearly Dividend Yield of 1.60%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 2.02, PHN has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.81, PHN has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.6%

5.2 History

  • The dividend of PHN is nicely growing with an annual growth rate of 11.21%!
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 39.70% of the earnings are spent on dividend by PHN. This is a low number and sustainable payout ratio.
  • The dividend of PHN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP39.7%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMANUTRA SPA

BIT:PHN (2/6/2026, 5:29:20 PM)

61.9

-0.7 (-1.12%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-10
Earnings (Next)03-13
Inst Owners17.49%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap599.19M
Revenue(TTM)180.41M
Net Income(TTM)24.16M
Analysts82.86
Price Target83.98 (35.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.6%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP39.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.65%
PT rev (3m)1.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.39%
Revenue NQ rev (1m)2.53%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.65%
Valuation
Industry RankSector Rank
PE 24.66
Fwd PE 25.35
P/S 3.32
P/FCF 57.48
P/OCF 41.47
P/B 9.06
P/tB 14.36
EV/EBITDA 13.78
EPS(TTM)2.51
EY4.05%
EPS(NY)2.44
Fwd EY3.95%
FCF(TTM)1.08
FCFY1.74%
OCF(TTM)1.49
OCFY2.41%
SpS18.64
BVpS6.83
TBVpS4.31
PEG (NY)3.95
PEG (5Y)1.69
Graham Number19.64
Profitability
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROCE 44.34%
ROIC 25.72%
ROICexc 34.17%
ROICexgc 53.82%
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
FCFM 5.78%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Debt/EBITDA 0.37
Cap/Depr 112.59%
Cap/Sales 2.23%
Interest Coverage 250
Cash Conversion 33.69%
Profit Quality 43.15%
Current Ratio 2.19
Quick Ratio 1.86
Altman-Z 10.48
F-Score7
WACC7.97%
ROIC/WACC3.23
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%
EBIT growth 1Y10.97%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.16%
EBIT Next 3Y18.62%
EBIT Next 5Y9.65%
FCF growth 1Y164.53%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y18.84%
OCF growth 3Y0.14%
OCF growth 5Y11.34%

PHARMANUTRA SPA / PHN.MI FAQ

What is the fundamental rating for PHN stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.


Can you provide the valuation status for PHARMANUTRA SPA?

ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.


What is the profitability of PHN stock?

PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.


How financially healthy is PHARMANUTRA SPA?

The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.


Is the dividend of PHARMANUTRA SPA sustainable?

The dividend rating of PHARMANUTRA SPA (PHN.MI) is 6 / 10 and the dividend payout ratio is 39.7%.